CAS: 959687-66-2

Pioglitazone is a thiazolidinedione that has been used for the treatment of type 2 diabetes mellitus. It improves insulin resistance and increases peripheral glucose uptake in patients with this disease. Pioglitazone also has shown potential as a biomarker for bowel disease and may be useful in the management of congestive heart failure. Pioglitazone increases transcriptional regulation and decreases hepatic steatosis, but it does not have any effects on energy metabolism or bone cancer. This drug interacts with other drugs by inhibiting their metabolism and may lead to adverse side effects such as congestive heart failure, hepatic steatosis, or bone cancer.